We are live on ! Find out more
WJA

Williams Jones & Associates Portfolio holdings

AUM $4.82B
1-Year Est. Return 19.95%
This Fund
S&P 500
This Quarter Est. Return
+5.51%
1 Year Est. Return
+19.95%
3 Year Est. Return
+72.12%
5 Year Est. Return
+86.19%
10 Year Est. Return
AUM
$4.54B
AUM Growth
+$227M
Cap. Flow
+$50M
Cap. Flow %
1.1%
Top 10 Hldgs %
24.93%
Holding
489
New
37
Increased
114
Reduced
194
Closed
39

Top Buys

Rank Stock Value
1
PYPL icon
PayPal
PYPL
+$34.7M
2
ZTS icon
Zoetis
ZTS
+$27.8M
3
CHX
ChampionX
CHX
+$22.6M
4
WP
Worldpay, Inc.
WP
+$20.7M
5
ROP icon
Roper Technologies
ROP
+$13.1M

Top Sells

Rank Stock Value
1
DOV icon
Dover
DOV
+$20.3M
2
META icon
Meta Platforms (Facebook)
META
+$14.1M
3
MHK icon
Mohawk Industries
MHK
+$13.4M
4
XRAY icon
Dentsply Sirona
XRAY
+$10.1M
5
TTD icon
Trade Desk
TTD
+$8.92M

Sector Composition

Rank Sector Weight
1 Technology 16.36%
2 Financials 13.95%
3 Healthcare 12.92%
4 Industrials 10.92%
5 Communication Services 8.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDXG icon
376
MiMedx Group
MDXG
$609M
$118K ﹤0.01%
18,500
EXG icon
377
Eaton Vance Tax-Managed Global Diversified Equity Income Fund
EXG
$3.04B
$105K ﹤0.01%
11,243
GOGL
378
DELISTED
Golden Ocean Group
GOGL
$101K ﹤0.01%
11,700
TK icon
379
Teekay
TK
$981M
$95K ﹤0.01%
12,200
PETX
380
DELISTED
Aratana Therapeutics, Inc.
PETX
$81K ﹤0.01%
19,045
-12,475
-40% -$62.9K
HIX
381
Western Asset High Income Fund II
HIX
$353M
$78K ﹤0.01%
12,085
PVLA
382
Palvella Therapeutics
PVLA
$2.23B
$71K ﹤0.01%
175
EGLE
383
DELISTED
Eagle Bulk Shipping Inc.
EGLE
$56K ﹤0.01%
1,429
-1,352
-49% -$51.6K
AST
384
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$41K ﹤0.01%
30,100
+10,000
+50% +$15.3K
IMDX
385
Insight Molecular Diagnostics
IMDX
$155M
$39K ﹤0.01%
+764
New +$37.6K
RGN
386
DELISTED
REGENERX BIOPHARMACEUTICALS
RGN
$30K ﹤0.01%
150,000
TRQ
387
DELISTED
Turquoise Hill Resources Ltd
TRQ
$28K ﹤0.01%
1,000
IW
388
DELISTED
IMAGEWARE SYSTEMS,INC
IW
$22K ﹤0.01%
+20,000
New +$22K
ADNT icon
389
Adient
ADNT
$1.45B
-15,748
Closed -$941K
ALLY icon
390
Ally Financial
ALLY
$13.4B
-21,400
Closed -$581K
AMLP icon
391
Alerian MLP ETF
AMLP
$12.9B
-2,425
Closed -$114K
ASC icon
392
Ardmore Shipping
ASC
$695M
-12,500
Closed -$95K
BUD icon
393
AB InBev
BUD
$165B
-1,950
Closed -$214K
ED icon
394
Consolidated Edison
ED
$40.2B
-2,972
Closed -$232K
FRO icon
395
Frontline
FRO
$8.81B
-16,500
Closed -$73K
FXI icon
396
iShares China Large-Cap ETF
FXI
$4.29B
-6,900
Closed -$326K
LKFT
397
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
-6,645
Closed -$663K
GXC icon
398
State Street SPDR S&P China ETF
GXC
$476M
-3,200
Closed -$354K
HAE icon
399
Haemonetics
HAE
$3.87B
-4,050
Closed -$296K
HAIN icon
400
Hain Celestial
HAIN
$53.5M
-17,100
Closed -$548K

Similar funds

Williams Jones & Associates's Q2 2018 Portfolio in Review

As of Q2 2018, Williams Jones & Associates held 489 positions worth $4.54B, up 5.3% from $4.31B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Williams Jones & Associates's Q2 2018 filing shows 37 new, 114 increased, 194 reduced and 39 closed positions. Its largest new stake was ChampionX: 551,665 shares worth $23.1M. The largest sale was Dover, an estimated $20.3M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

  • Williams Jones & Associates's largest Q2 2018 buy was ChampionX: 551,665 shares worth $23.1M.
  • Williams Jones & Associates added most to PayPal in Q2 2018, an estimated $34.7M increase.
  • Williams Jones & Associates's biggest Q2 2018 reduction was Dover, cutting an estimated $20.3M.
  • Williams Jones & Associates fully exited Dentsply Sirona in Q2 2018, selling an estimated $10.1M.
  • Williams Jones & Associates's ten largest holdings make up 25% of its $4.54B portfolio in Q2 2018.
  • Williams Jones & Associates opened 37 new positions and closed 39 in Q2 2018.
  • Williams Jones & Associates's portfolio value rose 5.3% quarter-over-quarter to $4.54B.

Based on Williams Jones & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.